Current issues in bipolar disorder: A critical review

European Neuropsychopharmacology

Volumn 17, Issue 11, 2007, Pages 687-695

  Oswald, Pierre ^a   Souery, Daniel ^a   Kasper, Siegfried ^b   Lecrubier, Yves ^c   Montgomery, Stuart ^d   Wyckaert, Sabien ^e   Zohar, Joseph ^f   Mendlewicz, Julien ^a  

^a ERASME HOSPITAL   (Belgium)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f SHEBA MEDICAL CENTER   (Israel)

Author keywords

Bipolar disorder; Comorbidity; Depression; Epidemiology; Guidelines; Mania; Mood stabilizer

Indexed keywords

AGOMELATINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; INOSITOL; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRANQUILIZER; VALPROIC ACID; ZIPRASIDONE;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CHRONICITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG WITHDRAWAL; EUROPE; EXTRAPYRAMIDAL SYNDROME; HUMAN; MANIA; MORBIDITY; ONSET AGE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; WEIGHT GAIN;

BIPOLAR DISORDER; HUMANS;

EID: 34548694064     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.03.006     Document Type: Review

References (92)

1. Akiskal H.S., Yerevanian B.I., Davis G.C., King D., and Lemmi H. The nosologic status of borderline personality: clinical and polysomnographic study. Am. J. Psychiatry 142 2 (1985) 192-198 (Feb)
2. Allilaire J.F., Hantouche E.G., Sechter D., Bourgeois M., Azorin J.M., Lancrenon S., Chatenet-Duchêne L., and Akiskal H.S. Frequence et aspects cliniques du trouble bipolaire II dans une etude multicentrique Française: EPIDEP. L'encephale XXVII (2001) 149-158
3. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., and Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156 11 (1999) 1686-1696 (Nov)
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, (DSM-IV) (1994), American Psychiatric Press, Washington, DC
5. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder, revision. Am. J. Psychiatry 159 (2002) 1-50
6. Angst J. The course of affective disorders: II. Typology of bipolar manic-depressive illness. Arch. Psychiatr. Nervenkr. 226 (1978) 65-73
7. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J. Affect. Disord. 50 (1998) 143-151
8. Angst J., Gamma A., Benazzi F., Ajdiace V., Eich D., and Rôssler D. Toward a redefinition of bipolarity: epidemiology and proposed criteria for bipolar II, minor bipolar disorders and hypomania. J. Affect. Disord. 73 (2003) 133-146
9. Biederman J., Mick E., and Faraone S.V. Age dependent decline of ADHD symptoms revisited: impact of remission definition and symptom subtype. Am. J. Psychiatry 157 (2000) 816-818
10. Bowden C.L. Pharmacological treatment of bipolar disorder. In: Maj M., Akiskal S.H., et al. (Eds). Bipolar Disorder (2002), John Wiley & Sons, Ltd., West Sussex 191-277
11. Bowden C.L., Brugger A.M., Swann A.C., Calabrese J.R., Janicak P.G., Petty F., Dilsaver S.C., Davis J.M., Rush A.J., and Small J.G. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 271 12 (1994) 918-924 (Mar 23-30)
12. Bowden C.L., Calabrese J.R., Sachs G., Yatham L.N., Asghar S.A., Hompland M., Montgomery P., Earl N., Smoot T.M., and DeVeaugh-Geiss J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry 60 4 (2003) 392-400 (Apr)
13. Bowden C.L., Grunze H., Mullen J., Brecher M., Paulsson B., Jones M., Vagero M., and Svensson K. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry 66 1 (2005) 111-121 (Jan)
14. Brady K.T., and Lydiard R.B. Bipolar affective disorder and substance abuse. J. Clin. Psychopharmacol. 12 1 Suppl (1992) 17S-22S (Feb)
15. Calabrese J.R., Bowden C.L., Sachs G.S., Ascher J.A., Monaghan E., and Rudd G.D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry 60 2 (1999) 79-88 (Feb)
16. Calabrese J.R., Bowden C.L., Sachs G., Yatham L.N., Behnke K., Mehtonen O.P., Montgomery P., Ascher J., Paska W., Earl N., and DeVeaugh-Geiss J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry 64 9 (2003) 1013-1024 (Sep)
17. Calabrese J.R., Vieta E., and Shelton M.D. Latest maintenance data on lamotrigine in bipolar disorder. Eur. Neuropsychopharmacol. 13 Suppl 2 (2003) S57-S66 (Aug)
18. Calabrese J.R., Kasper S., Johnson G., Tajima O., Vieta E., Yatham L.N., and Young A.H. International Consensus Group on Bipolar I Depression Treatment Guidelines. J. Clin. Psychiatry 65 4 (2004) 571-579 (Apr)
19. Calabrese J.R., Keck Jr. P.E., Macfadden W., Minkwitz M., Ketter T.A., Weisler R.H., Cutler A.J., McCoy R., Wilson E., and Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry 162 7 (2005) 1351-1360 (Jul)
20. Cassano G.B., Pini S., Saettoni M., Rucci P., and Dell'Osso L. Occurrence and clinical correlates of psychiatric comorbidity in patients with psychotic disorders. J. Clin. Psychiatry 59 (1998) 60-68
21. Cohn J.B., Collins G., Ashbrook E., and Wernicke J.F. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int. Clin. Psychopharmacol. 4 4 (1989) 313-322 (Oct)
22. Costello E.J., Farmer E.M., Angold A., Burns B.J., and Erkanli A. Psychiatric disorders among American Indian and white youth in Appalachia: the Great Smoky Mountains Study. Am. J. Public Health 87 5 (1997) 827-832 (May)
23. Davis L.L., Bartolucci A., and Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J. Affect. Disord. 85 3 (2005) 259-266 (Apr)
24. Faraone S.V., Biederman J., Mennin D., Wozniak J., and Spencer T. Attention-deficit hyperactivity disorder with bipolar disorder: a familial subtype?. J. Am. Acad. Child Adolesc. Psych. 36 10 (1997) 1378-1387 (Oct)
25. Faraone S.V., Biederman J., and Monuteaux M.C. Attention deficit hyperactivity disorder with bipolar disorder in girls: further evidence for a familial subtype?. J. Affect. Disord. 64 1 (2001) 19-26 (Apr)
26. Faravelli C., Guerrini Degl'Innocenti B., Aiazzi L., Incerpi G., and Pallanti S. Epidemiology of mood disorders: a community survey in Florence. J. Affect. Disord. 20 2 (1990) 135-141 (Oct)
27. Gao K., and Calabrese J.R. Newer treatment studies for bipolar depression. J. Bipolar Disord. 7 suppl 5 (2005) 13-23
28. Geddes J.R., Burgess S., Hawton K., Jamison K., and Goodwin G.M. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry 161 (2004) 217-222
29. Geller B., Williams M., Zimerman B., Frazier J., Beringer L., and Warner K.L. Prepubertal and early adolescent bipolarity differentiate from ADHD by manic symptoms, grandiose delusions, ultra-rapid or untradian cycling. J. Affect. Disord. 51 2 (1998) 81-91
30. Gijsman H.J., Geddes J.R., Rendell J.M., Nolen W.A., and Goodwin G.M. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry 161 9 (2004) 1537-1547 (Sep)
31. Goodwin G.M., and Young A.H. The British Association for Psychopharmacology guidelines for treatment of bipolar disorder: a summary. J. Psychopharmacol. 17 4 Suppl (2003) 3-6 (Dec)
32. Grunze H., Kasper S., Goodwin G., Bowden C., Baldwin D., Licht R., Vieta E., and Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders: Part I. Treatment of bipolar depression. World J. Biol. Psychiatry 3 3 (2002) 115-124 (Jul)
33. Grunze H., Kasper S., Goodwin G., et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Part II. Treatment of mania. World J. Biol. Psychiatry 4 (2003) 5-13
34. Grunze H., Kasper S., Goodwin G., Bowden C., and Moller H. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Part III. Maintenance treatment. World J. Biol. Psychiatry 5 (2004) 120-135
35. Halmi K.A., Eckert E., Marchi P., Sampugnaro V., Apple R., and Cohen J. Comorbidity of psychiatric diagnoses in anorexia nervosa. Arch. Gen. Psychiatry 48 8 (1991) 712-718 (Aug)
36. Hirschfeld R., and Kasper S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int. J. Neuropsychopharmacol 7 (2004) 507-522
37. Hirschfeld R., Baker J.D., Wozniak P., Tracy K., and Sommerville K.W. The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. J. Clin. Psychiatry 64 7 (2003) 841-846 (Jul)
38. Hirschfeld R.M., Keck Jr. P.E., Kramer M., Karcher K., Canuso C., Eerdekens M., and Grossman F. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am. J. Psychiatry 161 6 (2004) 1057-1065 (Jun)
39. Hirschfeld R.M.A., Sachs G., Calabrese, et al. The impact of lamotrigine on core symptoms in the acute treatment of bipolar depresión. Abstract of the 45th NCDEU Annual Meeting, Boca Raton, FL, June 6-9, 2005 (2005)
40. Kasper S., and Attarbaschi T. Treatment options for bipolar mania. Clin. Approaches Bipolar Disord. 3 (2004) 24-32
41. Keck. The Expert Consensus Guideline Series. Medication Teatment of Bipolar Disorder 2004 (2004)
42. Keck Jr. P.E., Versiani M., Potkin S., West S.A., Giller E., and Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am. J. Psychiatry 160 4 (2003) 741-748 (Apr)
43. Keck Jr. P.E., Marcus R., Tourkodimitris S., Ali M., Liebeskind A., Saha A., and Ingenito G. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry 160 9 (2003) 1651-1658 (Sep)
44. Kessler R.C., Adler L.A., Barkley R., Biederman J., Conners C.K., Faraone S.V., Greenhill L.L., Jaeger S., Secnik K., Spencer T., Ustun T.B., and Zaslavsky A.M. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol. Psychiatry 57 11 (2005) 1442-1451 (Jun 1)
45. Khanna S., Vieta E., Lyons B., Grossman F., Eerdekens M., and Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br. J. Psychiatry 187 (2005) 229-234 (Sep)
46. Kooij J.J., Buitelaar J.K., van den Oord E.J., Furer J.W., Rijnders C.A., and Hodiamont P.P. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol. Med. 35 6 (2005) 817-827 (Jun)
47. Koukopoulos A., Sani G., Koukopoulos A.E., Minnai G.P., Girardi P., Pani L., Albert M.J., and Reginaldi D. Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. J. Affect. Disord. 73 1-2 (2003) 75-85 (Jan)
48. Kruger S., Cooke R.G., Hasey G.M., et al. Comorbidity of obsessive-compulsive disorder in bipolar disorder. J. Affect. Disord. 34 (1995) 117-120
49. Lewinsohn P.M., Klein D.N., and Seeley J.R. Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. J. Am. Acad. Child Adolesc. Psych. 34 4 (1995) 454-463 (Apr)
50. Licht R., Vestergaard P., Kessing L., Larsen J., and Thomsen P. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr. Scand., Suppl. 419 (2003) 1-22
51. Massat I., and Victoor L. Early Bipolar disorder and ADHD: differences and similarities in pre-pubertal and early adolescence. Clin. Approaches Bipolar Disord. 4 (2005) 20-28
52. McElroy S.L., Strakowski S.M., Keck Jr. P.E., Tugrul K.L., West S.A., and Lonczak H.S. Differences and similarities in mixed and pure mania. Compr. Psychiatry 36 3 (1995) 187-194 (May-Jun)
53. McElroy S.L., Altshuler L.L., Suppes T., Keck Jr. P.E., Frye M.A., Denicoff K.D., Nolen W.A., Kupka R.W., Leverich G.S., Rochussen J.R., Rush A.J., and Post R.M. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am. J. Psychiatry 158 3 (2001) 420-426 (Mar)
54. Meltzer H., Gatward R., Goodman R., and Ford T. Mental health of children and adolescents in Great Britain. Int. Rev. Psychiatry 15 1-2 (2003) 185-187 (Feb-May)
55. Mendlewicz J., and Youdim M.B. Antidepressant potentiation of 5-hydroxytryptophan by l-deprenyl in affective illness. J. Affect. Disord. 2 (1980) 137-146
56. Miklowitz D.J., George E.L., Richards J.A., Simoneau T.L., and Suddath R.L. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch. Gen. Psychiatry 60 9 (2003) 904-912 (Sep)
57. Milberger S., Biederman J., Faraone S.V., Murphy J., and Tsuang M.T. Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms. Am. J. Psychiatry 152 12 (1995) 1793-1799 (Dec)
58. Mitchell P.B. RANZCP clinical practice guidelines. Summary of guideline for the treatment of bipolar disorder. Aust. Psychiatry 11 1 (2003)
59. Morgan V.A., Mitchell P.B., and Jablensky A.V. The epidemiology of bipolar disorder: sociodemographic, disability and service utilization data from the Australian National Study of Low Prevalence (Psychotic) Disorders. Bipolar Disord. 7 4 (2005) 326-337 (Aug)
60. Nemeroff C.B., Evans D.L., Gyulai L., Sachs G.S., Bowden C.L., Gergel I.P., Oakes R., and Pitts C.D. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am. J. Psychiatry 158 6 (2001) 906-912 (Jun)
61. Nierenberg A.A., Miyahara S., Spencer T., Wisniewski S.R., Otto M.W., Simon N., Pollack M.H., Ostacher M.J., Yan L., Siegel R., and Sachs G.S. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol. Psychiatry 57 11 (2005) 1467-1473 (Jun 1)
62. Osby U., Brandt L., Correia N., Ekbom A., and Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 58 9 (2001) 844-850 (Sep)
63. Oswald P., Souery D., Kasper S., Lecrubier Y., Montgomery S.A., Zohar J., and Mendlewicz J. Predictive factors of resistance to antidepressants in bipolar depression: results from a European multicentre study. Eur. Neuropsychopharmacol. 16 suppl 1 (2006) S83
64. Pini S., de Queiroz V., Pagnin D., Pezawas L., Angst J., Cassano G.B., and Wittchen H.U. Prevalence and burden of bipolar disorders in European countries. Eur. Neuropsychopharmacol. 15 4 (2005) 425-434 (Aug)
65. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., and Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264 19 (1990) 2511-2518 (Nov 21)
66. Sachs G.S., Printz D.J., Kahn D.A., Carpenter D., and Docherty J.P. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad. Med.; Spec No:1-104 (2000)
67. Scott J., and Colom S. Psychosocial treatments for bipolar disorders. Psychiatr. Clin. North Am. 28 2 (2005) 371-384 (Jun)
68. Scully P.J., Owens J.M., Kinsella A., and Waddington J.L. Schizophrenia, schizoaffective and bipolar disorder within an epidemiologically complete, homogeneous population in rural Ireland: small area variation in rate. Schizophr. Res. 67 2-3 (2004) 143-155 (Apr 1)
69. Shelton R.C., and Stahl S.M. Risperidone and paroxetine given singly and in combination for bipolar depression. J. Clin. Psychiatry 65 12 (2004) 1715-1719 (Dec)
70. Simon N.M., Otto M.W., Weiss R.D., Bauer M.S., Miyahara S., Wisniewski S.R., Thase M.E., Kogan J., Frank E., Nierenberg A.A., Calabrese J.R., Sachs G.S., and Pollack M.H. Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J. Clin. Psychopharmacol. 24 5 (2004) 512-520 (Oct)
71. Simpson S.G., al-Mufti R., Andersen A.E., and DePaulo Jr. J.R. Bipolar II affective disorder in eating disorder inpatients. J. Nerv. Ment. Dis. 180 11 (1992) 719-722 (Nov)
72. Sonne S.C., Brady K.T., and Morton W.A. Substance abuse and bipolar affective disorder. J. Nerv. Ment. Dis. 182 6 (1994) 349-352 (Jun)
73. Strakowski S.M., Tohen M., Stoll A.L., Faedda G.L., and Goodwin D.C. Comorbidity in mania at first hospitalization. Am. J. Psychiatry 149 4 (1992) 554-556 (Apr)
74. Strakowski S.M., MeElroy S.L., Keck Jr. P.W., and West S.A. The co-occurrence of mania with medical and other psychiatric disorders. Int. J. Psychiatry Med. 24 4 (1994) 305-328
75. Suppes T., Dennehy E.B., Hirschfeld R.M., Altshuler L.L., Bowden C.L., Calabrese J.R., Crismon M.L., Ketter T.A., Sachs G.S., and Swann A.C. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry 66 7 (2005) 870-886 (Jul)
76. Szadoczky E., Papp Z., Vitrai J., Rihmer Z., and Furedi J. The prevalence of major depressive and bipolar disorders in Hungary. Results from a national epidemiologic survey. J. Affect. Disord. 50 2-3 (1998) 153-162 (Sep)
77. ten Have M., Vollebergh W., Bijl R., and Nolen W.A. Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilisation): results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). J. Affect. Disord. 68 2-3 (2002) 203-213 (Apr)
78. Thase M. Bipolar depression: issues in diagnosis and treatment. Harv. Rev. Psychiatry 13 5 (2005) 257-271 (Sep-Oct)
79. Thase M., Macfadden F., McCoy R., Chang W., and Calabrese C. Confirmation of the efficacy of quetiapine monotherapy in bipolar depression in a second double-blind, placebo-controlled study: The BOLDER II Study. Annual Meeting of the American Psychiatric Association, Toronto, Canada, research poster board NR600 (2006)
80. Tohen M., Sanger T.M., McElroy S.L., Tollefson G.D., Chengappa K.N., Daniel D.G., Petty F., Centorrino F., Wang R., Grundy S.L., Greaney M.G., Jacobs T.G., David S.R., and Toma V. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. J. Psychiatry 156 5 (1999) 702-709 (May)
81. Tohen M., Jacobs T.G., Grundy S.L., McElroy S.L., Banov M.C., Janicak P.G., Sanger T., Risser R., Zhang F., Toma V., Francis J., Tollefson G.D., and Breier A. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch. Gen. Psychiatry 57 9 (2000) 841-849 (Sep)
82. Tohen M., Baker R.W., Altshuler L.L., Zarate C.A., Suppes T., Ketter T.A., Milton D.R., Risser R., Gilmore J.A., Breier A., and Tollefson G.A. Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry 159 6 (2002) 1011-1017 (Jun)
83. Tohen M., Ketter T.A., Zarate C.A., Suppes T., Frye M., Altshuler L., Zajecka J., Schuh L.M., Risser R.C., Brown E., and Baker R.W. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am. J. Psychiatry 160 7 (2003) 1263-1271 (Jul)
84. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., Mitchell P.B., Centorrino F., Risser R., Baker R.W., Evans A.R., Beymer K., Dube S., Tollefson G.D., and Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 60 11 (2003) 1079-1088 (Nov)
85. Tohen M., Chengappa K.N., Suppes T., Baker R.W., Zarate C.A., Bowden C.L., Sachs G.S., Kupfer D.J., Ghaemi S.N., Feldman P.D., Risser R.C., Evans A.R., and Calabrese J.R. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br. J. Psychiatry 184 (2004) 337-345 (Apr)
86. Vieta E., and Goikolea J.M. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord. 7 Suppl 4 (2005) 21-33
87. Vieta E., Bourin M., Sanchez R., Marcus R., Stock E., McQuade R., Carson W., Abou-Gharbia N., Swanink R., and Iwamoto T. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br. J. Psychiatry 187 (2005) 235-242 (Sep)
88. Wittchen H.U., Nelson C.B., and Lachner G. Prevalence of mental disorders and psycosocial impairments in adolescents and young adults. Psychol. Med. 28 1 (1998) 109-126
89. Wittchen H.U., Mhlig S., and Pezawas L. Natural course and burden of bipolar disorders. Int. J. Neuropsychopharmacol. 6 2 (2003) 145-154 (Jun)
90. Yatham L.N., Kennedy S.H., O'Donovan C., Parikh S., MacQueen G., McIntyre R., Sharma V., Silverstone P., Alda M., Baruch P., Beaulieu S., Daigneault A., Milev R., Young L.T., Ravindran A., Schaffer A., Connolly M., and Gorman C.P. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 7 Suppl 3 (2005) 5-69
91. Yatham L.N., Kennedy S.H., O'Donovan C., Parikh S., MacQueen G., McIntyre R., Sharma V., and Beaulieu S. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 8 (2006) 721-739
92. Young L.T., Cooke R.G., Robb J.C., Levitt A.J., and Joffe R.T. Anxious and non-anxious bipolar disorder. J. Affect. Disord. 29 1 (1993) 49-52